×

The reality of MS fatigue and its impact on daily life

Rafael Lara, who goes by Macho, shares his experience living with multiple sclerosis fatigue, including how it affects his daily routines, energy levels, and ability to spend quality time with his family while navigating life with MS. The post The reality of MS fatigue and…

AAN 2026: Fenebrutinib outperforms Aubagio for treating relapsing MS

The experimental drug fenebrutinib was shown to significantly outperform Aubagio (teriflunomide), an approved therapy, in reducing relapses and MRI markers of disease activity in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from a pair of largely identical Phase 3…

Scientists studying yak genetics discover myelin repair mechanism

A team of scientists in China, attempting to understand the function of a genetic mutation commonly found in animals living at high altitudes, discovered a previously unknown mechanism key to myelin repair. The discovery could have important implications for diseases such as multiple sclerosis (MS),…

Bloody Statistics..And Alemtuzumab

Tweet I have been taken to task out my slipshod use of statistics and suggested about 50% get disease control after two doses and about 50% after three doses so that with three doses about 75% of people get control. Yep I have not referenced…

AAN 2026: GA Depot may help stabilize disability in RMS and PPMS

Mapi Pharma’s long-acting formulation of glatiramer acetate, GA Depot, may help stabilize disability scores over time in people with both relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). That’s according to new analyses of data from an open-label Phase 2a clinical trial…

Spring Sunshine Fruit Salad

Spring is finally here and it’s time to enjoy the delicious fruits available this time of year. If you’re looking for a last-minute dish that’s healthy and requires zero cooking, this fruit salad is your new go-to. It’s crisp, refreshing, and … Continue reading → Source:…

AAN 2026: Top-tier MS drugs out of reach for many on Medicaid

Medicaid coverage of highly effective disease-modifying therapies (DMTs) for multiple sclerosis (MS) varies across the U.S., with some states offering no access at all, a study reported. The research suggests that where a person lives could influence whether they receive high-efficacy therapies, which are known…

AAN2026 CLAD 5 years on. What to Do?

Tweet With Alemtuzumab about 50% of people need a thrid dose because of disease breakthrough and only about 50% of them would need a forth course because of disease breakthrough. The result is when there is disease breakthrough another dose was given. Cladribine development was…